Significant analyst price target increase of $11 per share with maintained overweight recommendation, coupled with positive clinical trial data for key pipeline drugs showing therapeutic potential in large markets (heart disease and muscular dystrophy).
Articles that tag EWTX but are mainly about other companies.
Early-stage competitor with EDG-7500 in phase II trials for oHCM and nHCM, with phase III targeted for Q4 2026. Still in development stage with no approved products, representing potential future competition but not yet a market threat.
Company is identified as a potential future competitor with EDG-7500 in phase II studies for HCM, with phase III targeted for Q4 2026. This represents early-stage pipeline development without specific efficacy data or approval milestones.
Mentioned only as the previous employer of the newly appointed CMO. No direct business impact or developments related to Edgewise are discussed in the article.
Company has two promising drug candidates with clear catalysts in 2026. EDG-7500 demonstrates superior safety profile (0% ejection fraction drop vs 21.5% for competitors) with efficacy data expected June 2026. Sevasemten addresses an unmet medical need in BMD with zero current treatments and strong preview data showing disease stabilization. High short interest (15.6%) could amplify positive moves. Stock has tripled from 52-week lows with $530M cash position supporting development.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
